Spectranetics (NSDQ:SPNC) announced this week that it plans to launch a senior note funding round in order to support its $230 million bid to acquire AngioScore and its portfolio of angioplasty catheters.
Spectranetics plans to offer $200 million in convertible senior notes due 2034, and expects to grant underwriters a 30-day option to purchase up to $30 million more.
The funds will help Spectranetics finance the acquisition, which consists of $115 million in cash and $115 million in Spectranetics common stock, with additional payouts pending certain regulatory and commercial achievements.
Sign up to get our
free newsletters delivered right to your inbox.
The AngioScore buy fits snugly within Spectranetics’ growth strategy, according to Spectranetics president & CEO Scott Drake.
"AngioScore meets our criteria with an exceptional strategic fit, leverageable call points, differentiated technology and clear operating efficiencies,” Drake said in prepared remarks. "As a combined entity, we expect to have a meaningfully expanded market opportunity and a compelling product portfolio.”
“Simply put, we are ‘better together’,” AngioScore president & CEO Thomas Trotter added. “We believe that this combination provides an opportunity to build a remarkable future while delivering life-impacting technologies to physicians and patients. In Spectranetics, we find a like-minded partner that shares our values, our commitment to improving patients’ lives, and equally high standards for operational excellence and quality.”
Together the companies accounted for pro forma revenues of $213.5 million in 2013, and Spectranetics expects the acquisition to be accretive to adjusted earnings starting in 2015.